StockNews.com began coverage on shares of Omeros (NASDAQ:OMER – Get Rating) in a research report report published on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Separately, UBS Group lowered shares of Omeros from a buy rating to a neutral rating in a research report on Thursday, December 8th.
Omeros Stock Down 9.9 %
Shares of OMER stock opened at $3.54 on Thursday. The firm has a market cap of $222.42 million, a PE ratio of 4.72 and a beta of 1.02. Omeros has a 12 month low of $1.74 and a 12 month high of $7.75. The stock has a 50 day moving average of $3.61 and a 200-day moving average of $3.28. The company has a quick ratio of 7.30, a current ratio of 3.25 and a debt-to-equity ratio of 2.58.
Institutional Inflows and Outflows
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
- Get a free copy of the StockNews.com research report on Omeros (OMER)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.